SG11202002933TA - Compositions for booster vaccination against dengu - Google Patents

Compositions for booster vaccination against dengu

Info

Publication number
SG11202002933TA
SG11202002933TA SG11202002933TA SG11202002933TA SG11202002933TA SG 11202002933T A SG11202002933T A SG 11202002933TA SG 11202002933T A SG11202002933T A SG 11202002933TA SG 11202002933T A SG11202002933T A SG 11202002933TA SG 11202002933T A SG11202002933T A SG 11202002933TA
Authority
SG
Singapore
Prior art keywords
dengu
compositions
vaccination against
booster vaccination
booster
Prior art date
Application number
SG11202002933TA
Inventor
Diana Coronel
Betzana Zambrano
Fernando Noriega
Tram Anh Wartel
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of SG11202002933TA publication Critical patent/SG11202002933TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202002933TA 2017-10-05 2018-10-05 Compositions for booster vaccination against dengu SG11202002933TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762568525P 2017-10-05 2017-10-05
PCT/IB2018/001219 WO2019069130A1 (en) 2017-10-05 2018-10-05 Compositions for booster vaccination against dengu

Publications (1)

Publication Number Publication Date
SG11202002933TA true SG11202002933TA (en) 2020-04-29

Family

ID=64184125

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002933TA SG11202002933TA (en) 2017-10-05 2018-10-05 Compositions for booster vaccination against dengu

Country Status (6)

Country Link
US (2) US11690903B2 (en)
EP (1) EP3691681A1 (en)
JP (1) JP7313345B2 (en)
AU (1) AU2018346724A1 (en)
SG (1) SG11202002933TA (en)
WO (1) WO2019069130A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123470A1 (en) * 2020-12-10 2022-06-16 Reagene Biosciences Pvt. Ltd. Saliva based diagnostic assays for detection of sarscov2 receptor binding domain (rbd) neutralizing antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
ATE297757T1 (en) 1997-02-28 2005-07-15 Acambis Inc CHIMERIC VACCINES AGAINST FLAVIVIRUS
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
WO2000057910A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
AU4178300A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
AU4179200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
PT2278012E (en) 2000-02-16 2015-11-30 Univ Mahidol Immunogenic dengue 2 virus chimeras
PT1159968E (en) 2000-05-30 2008-11-20 Univ Mahidol Attenuated strains of dengue virus and their use in a vaccine composition
AT410634B (en) 2001-02-21 2003-06-25 Franz X Dr Heinz ATTENUATED LIFE VACCINE
WO2002095075A1 (en) 2001-05-22 2002-11-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
CA2473321C (en) 2002-01-15 2015-10-06 Acambis, Inc. Flavivirus vaccines
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
KR101582163B1 (en) 2005-06-17 2016-01-05 사노피 파스퇴르 Dengue serotype 2 attenuated strain
CA2611934C (en) 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
BRPI0618850A2 (en) 2005-11-21 2011-09-13 Sanofi Pasteur Ltd stabilization formulations for recombinant viruses
CU23586A1 (en) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech METHODS AND PROTEINS FOR THE PROPHLACTIC AND / OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF THE DENGUE VIRUS AND OTHER FLAVIVIRUS
US7968102B2 (en) 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (en) 2006-07-12 2008-01-18 Sanofi Pasteur Sa IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE
FR2906724B1 (en) 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
FR2909286B1 (en) 2006-12-01 2012-06-08 Sanofi Pasteur IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE
US8591916B2 (en) 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
WO2009134717A1 (en) 2008-04-30 2009-11-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (en) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CA2769645A1 (en) 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
MX2012012681A (en) 2010-05-21 2012-12-17 Univ Pittsburgh Universal dengue virus sequences and methods of use.
WO2012051491A1 (en) 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
BR112015001313A2 (en) 2012-07-24 2017-08-01 Sanofi Pasteur vaccine compositions
KR20150036592A (en) 2012-07-24 2015-04-07 사노피 파스퇴르 Vaccine compositions
TW201620546A (en) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 Vaccine compositions
US10518409B2 (en) * 2014-09-02 2019-12-31 Mark Oleynik Robotic manipulation methods and systems for executing a domain-specific application in an instrumented environment with electronic minimanipulation libraries
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.

Also Published As

Publication number Publication date
US11690903B2 (en) 2023-07-04
AU2018346724A1 (en) 2020-05-14
EP3691681A1 (en) 2020-08-12
JP2020536107A (en) 2020-12-10
US20230338504A1 (en) 2023-10-26
JP7313345B2 (en) 2023-07-24
US20200289637A1 (en) 2020-09-17
WO2019069130A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
IL273541A (en) Formulations
IL268697A (en) Formulations
ZA201801035B (en) Vaccine compositions
IL269630A (en) Niraparib formulations
IL269621A (en) Niraparib formulations
IL265609A (en) Novel formulations
IL273282A (en) Niraparib formulations
GB201607918D0 (en) Novel formulations
GB201610599D0 (en) Immunogenic Composition
SG11202010821TA (en) Vaccine composition
GB201711635D0 (en) Immunogenic composition
IL259575B (en) Immunostimulatory compositions
GB201711637D0 (en) Immunogenic composition
SG11202009147UA (en) Vaccine compositions
GB201614485D0 (en) Immunogenic composition
HK1243341A1 (en) Reduced foaming vaccine compositions
GB2562241B (en) Vaccine compositions
IL271603A (en) Immunogenic compositions
GB201604755D0 (en) Immunogenic compositions
GB201703529D0 (en) Vaccine composition
SG11202002933TA (en) Compositions for booster vaccination against dengu
EP3710051A4 (en) Vaccine compositions
EP3677276A4 (en) Vaccine composition
GB2564901B (en) Vaccine compositions
GB201809541D0 (en) Vaccine compositions